Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 24:12:986903.
doi: 10.3389/fonc.2022.986903. eCollection 2022.

LAG-3+ tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients

Guoming Hu  1   2   3 , Shimin Wang  4 , Songxiang Wang  1 , Qiannan Ding  5 , Liming Huang  1
Affiliations

LAG-3+ tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients

Guoming Hu et al. Front Oncol. .

Abstract

Purpose: Immune checkpoint molecule lymphocyte-activating gene-3 (LAG-3), which is expressed on active lymphocytes, has proven to be associated with immunosuppression and cancer progression in a variety of solid tumors. However, the role of LAG-3+ lymphocytes in human breast cancer (BC) is still not conclusive. We therefore performed a meta-analysis to clarify the role of these cells in prognosis prediction for BC.

Methods: We searched PubMed, Embase, and EBSCO to identify the studies evaluating the association of LAG-3+ lymphocyte infiltration and overall survival (OS) and/or disease-free survival (DFS) in BC patients, then combined extracted data with STATA 12.0.

Results: Eight published studies involving 5,859 BC patients were incorporated into this meta-analysis. We noted that a high number of LAG-3+ tumor-infiltrating lymphocytes were not appreciably associated with OS and DFS in BC patients. Strikingly, in stratified analyses based on the molecular type of BC, LAG-3+ lymphocyte infiltration was remarkably associated with better OS rather than DFS in triple-negative breast cancer (TNBC), whereas it significantly influenced neither OS nor DFS in Her2-positive BC. However, an increased density of these lymphocytes indicated a trend for better OS in Her2-positive BC. In addition, we found that LAG-3+ lymphocyte infiltration was also remarkably associated with prolonged OS in Her2-positive BC patients when they were measured by immunohistochemistry (IHC). In addition, an elevated number of these lymphocytes did not correlate with pathological complete response rate or clinicopathological features including lymph node metastasis.

Conclusion: The infiltration of LAG-3+ lymphocytes ameliorates OS in TNBC and Her2-positive BC, implicating that it is a valuable prognostic biomarker, and applications of anti-LAG-3 antagonists may possibly be not a promising therapeutic strategy for human BC especially for TNBC.

Keywords: LAG-3+tumor-infiltrating lymphocytes; favorable prognosis; meta-analysis; triple-negative breast cancer; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Forest plots describing HR of the association between LAG-3+ tumor-infiltrating lymphocytes and OS in breast cancer patients.
Figure 2
Figure 2
Stratified analyses describing HRs of the association between LAG-3+ tumor-infiltrating lymphocytes and OS in TNBC and Her2-positive breast cancer. TNBC, triple-negative breast cancer.
Figure 3
Figure 3
Stratified analyses describing HRs of the association between LAG-3+ tumor-infiltrating lymphocytes and OS in TNBC and Her2-positive breast cancer according to the detection methods. TNBC, triple-negative breast cancer; IHC, immunohistochemistry; NGS, “Next-generation” sequencing technology.
Figure 4
Figure 4
Forest plots describing HR of the association between LAG-3+ tumor-infiltrating lymphocytes and DFS in breast cancer patients.
Figure 5
Figure 5
Stratified analyses describing HRs of the association between the LAG-3+ tumor-infiltrating lymphocytes and DFS in TNBC and Her2-positive breast cancer. TNBC, triple-negative breast cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: Cancer and other tales. Nat Rev Immunol (2011) 11(10):702–11. doi: 10.1038/nri3064 - DOI - PubMed
    1. Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol (2021) 12:731798. doi: 10.3389/fphar.2021.731798 - DOI - PMC - PubMed
    1. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. . Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin Cancer Res (2019) 25(15):4592–602. doi: 10.1158/1078-0432.Ccr-18-1538 - DOI - PMC - PubMed
    1. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl J Med (2018) 379(22):2108–21. doi: 10.1056/NEJMoa1809615 - DOI - PubMed
    1. Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol (2019) 42:101305. doi: 10.1016/j.smim.2019.101305 - DOI - PMC - PubMed

Publication types